AstraZeneca PLC (AZN) vs Gilead Sciences, Inc. (GILD)
GILD leads on 12 of 17 compared metrics.
A side-by-side comparison of AstraZeneca PLC and Gilead Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 14, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — AZN vs GILD
growth of $100 · last 30yAZN +731.4%GILD +14253.1%GILD compounded faster
Log scale — wide-divergence pair
AZN GILD
AZN vs GILD: by the numbers
- •AZN is the larger company ($277.22B vs $155.93B market cap).
- •GILD trades at the lower earnings multiple (17.11 vs 26.92 P/E).
- •GILD converts more revenue to profit (30.99% vs 17.19% net margin).
- •AZN grew revenue faster over the past five years (16.99% vs 3.07% CAGR).
- •GILD pays the higher dividend yield (1.91% vs 1.79%).
Which is better, AZN or GILD?
Metric tally: AZN 5 · GILD 12It depends on what you're optimizing for:
ValueGILD(lower P/E)
GrowthAZN(faster 5Y revenue CAGR)
IncomeGILD(higher dividend yield)
QualityGILD(higher ROIC)
Valuation
| Metric | AZN | GILD |
|---|---|---|
| P/E ratio | 26.92 | 17.11● |
| Forward P/E | 15.33 | 13.00● |
| P/S ratio | 4.62● | 5.30 |
| P/B ratio | 5.90● | 6.70 |
| PEG ratio | 0.14 | 0.01● |
| EV / EBITDA | 14.92 | 12.91● |
| FCF yield | 2.89% | 6.49%● |
Profitability
| Metric | AZN | GILD |
|---|---|---|
| Gross margin | 81.68%● | 79.35% |
| Operating margin | 23.69% | 38.26%● |
| Net margin | 17.19% | 30.99%● |
| ROE | 21.95% | 39.19%● |
| ROIC | 13.03% | 21.53%● |
Dividends
| Metric | AZN | GILD |
|---|---|---|
| Dividend yield | 1.79% | 1.91%● |
| Payout ratio | 48.48% | 35.09% |
Growth (annualized)
| Metric | AZN | GILD |
|---|---|---|
| Revenue CAGR (5Y) | 16.99%● | 3.07% |
| EPS CAGR (5Y) | 22.02% | 133.83%● |
| FCF CAGR (5Y) | 15.68%● | 3.30% |
| Total return CAGR (5Y) | 11.03% | 17.06%● |
Frequently asked
- Which is better, AZN or GILD?
- It depends on your goal. value: GILD (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: GILD (higher dividend yield); quality: GILD (higher ROIC). Across all compared metrics, GILD leads 12 to 5.
- Is AZN or GILD cheaper?
- On trailing earnings, GILD is cheaper: AZN trades at a 26.92 P/E and GILD at 17.11.
- Which has grown faster, AZN or GILD?
- Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus GILD at 3.07%.
- Does AZN or GILD pay a bigger dividend?
- AZN yields 1.79% and GILD yields 1.91% based on trailing dividends and the latest price.
- Is AZN or GILD more profitable?
- GILD runs the higher net margin — AZN at 17.19% versus GILD at 30.99%.
- Which has been the better investment, AZN or GILD?
- Over the past 10-year, AZN delivered the higher annualized total return — AZN at 15.77% versus GILD at 7.79%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AstraZeneca P/E ratioGilead Sciences P/E ratioAstraZeneca dividend yieldGilead Sciences dividend yieldAstraZeneca ROEGilead Sciences ROEAstraZeneca operating marginGilead Sciences operating marginAstraZeneca revenue growthGilead Sciences revenue growthAstraZeneca free cash flowGilead Sciences free cash flow
AstraZeneca & Gilead Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 14, 2026.